Carregant...
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
Lung cancer is the leading cause of mortality worldwide. Non-small cell lung cancer (NSCLC) is a particularly aggressive cancer, the optimum management of which is still being determined. In the metastatic disease, the standard therapy is a platinum-based combination chemotherapy; however, in spite...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3253753/ https://ncbi.nlm.nih.gov/pubmed/22241943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S22079 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|